Skip to main content
Clinical Trials/NCT00632190
NCT00632190
Completed
Not Applicable

Measurement of Fluorescence EEM of Cervical Intraepithelial Neoplasia

British Columbia Cancer Agency0 sites1,800 target enrollmentJanuary 2000

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cervical Cancer
Sponsor
British Columbia Cancer Agency
Enrollment
1800
Primary Endpoint
Measurement of reflection and fluorescence spectra in vivo of sites in the human cervix
Status
Completed
Last Updated
16 years ago

Overview

Brief Summary

RATIONALE: New diagnostic procedures, such as spectroscopy, may be a less invasive way to check for dysplasia and neoplasia in the cervix. Spectroscopy may also used as a screening test to help doctors find cervical cancer sooner, when it may be easier to treat.

PURPOSE: This clinical trial is studying how well spectroscopy works in diagnosing dysplasia and neoplasia in the cervix in women undergoing colposcopy or Pap testing.

Detailed Description

OBJECTIVES: * To identify potential improvements for a noninvasive method of diagnosing dysplasia and neoplasia in the cervix using fluorescence and reflectance spectroscopy. * To measure the reflection and fluorescence spectra in vivo of sites in the human cervix. * To further refine fluorescence spectroscopy for detection of cervical lesions via better classification of normal columnar tissue and non-neoplastic tissue with inflammation, and low- and high-grade squamous intraepithelial lesions. * Evaluate and validate the wavelength selections for the spectroscopy device derived from in vitro measurements. * Determine the sensitivity and specificity of this device for the diagnosis of cervical intraepithelial neoplasia. OUTLINE: This is a multicenter study. Patients are stratified according to menopausal status and current treatment (premenopausal not on oral contraceptive pills \[OCP\] vs premenopausal on OCP vs postmenopausal not on hormone replacement therapy \[HRT\] vs postmenopausal on HRT). * Diagnostic study: As part of routine colposcopic evaluation, patients undergo placement of the probe on 1 to 4 sites in the cervix for 2-5 minutes. Up to two colposcopically abnormal sites and two normal sites are biopsied. Blood is drawn for hormone levels. Fluorescence excitation and emission matrix (EEM) data and reflectance spectroscopic information is acquired from patients with an abnormal Papanicolaou smear. * Screening study: Fluorescence EEM and reflectance spectroscopic information is acquired from patients with a history of normal Papanicolaou smears. PROJECTED ACCRUAL: A total of 800 patients with abnormal Papanicolaou smears and 1000 subjects with normal Papanicolaou smears are accrued for this study.

Registry
clinicaltrials.gov
Start Date
January 2000
End Date
March 2003
Last Updated
16 years ago
Study Type
Interventional
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Measurement of reflection and fluorescence spectra in vivo of sites in the human cervix

Refinement of fluorescence spectroscopy for detection of cervical lesions via better classification of normal columnar tissue and non-neoplastic tissue with inflammation, and low- and high-grade squamous intraepithelial lesions

Validation of wavelength selections for the spectroscopy device derived from in vitro measurements

Sensitivity and specificity of this device for the diagnosis of cervical intraepithelial neoplasia

Similar Trials